Fig. 2: Distribution of Individual Case Safety Reports (ICSRs) by report type.
From: Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
ICSRs for CAR-T therapy were categorized by report type documented in VigiBase for (a) cardiac, (b) investigational, and (c) vascular adverse reactions from 2018 to 2022.
